Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Formaldoxime is a simple oxime compound (CH2=NOH) that has been investigated in preclinical research for its potential vasodilatory properties, particularly in the context of pulmonary hypertension. In experimental studies, it has been evaluated for its ability to induce relaxation in pulmonary and mesenteric arteries. While its exact mechanism of action in vascular tissues is not fully characterized, it is often studied alongside other nitrogen-containing compounds and hydroxamic acids that may act as nitric oxide (NO) donors or activators of the soluble guanylyl cyclase (sGC) pathway. Currently, formaldoxime is primarily utilized as a biochemical reagent and laboratory tool rather than a clinical therapeutic candidate.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on formaldoxime.